Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
1479 - 1481
Clin Infect Dis
MetadataShow full item record
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
AuthorsGrebely, J; Dore, GJ; Zeuzem, S; Aspinall, RJ; Fox, R; Han, L; McNally, J; Osinusi, A; Brainard, DM; Subramanian, GM; Natha, M; Foster, GR; Mangia, A; Sulkowski, M; Feld, JJ
- Immune Systems